A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer
This research study is a multicentre phase Ⅰb/Ⅱ Study to evaluate the efficacy and safety of the combination of Fluzoparib (SHR-3162) and temozolomide with or without SHR-1316 in small cell lung cancer
Small Cell Lung Cancer
DRUG: Fluzoparib|DRUG: temozolomide|BIOLOGICAL: SHR-1316
Phase Ⅰb: Number of Subjects Experienced Any Dose-Limiting Toxicity (DLT) over the DLT period., At the end of Cycle1 (each cycle is 21 days )|Phase Ⅰb: Determination of Recommended Phase II dose (RP2D) of Escalating Dose of Fluzoparib and temozolomide with or without SHR-1316., Up to approximately 2 Years|Phase Ⅱ: Progression Free Survival (PFS) at four months., Up to approximately 2 Years|Phase Ⅱ: Progression Free Survival (PFS) as Assessed by the Investigator according to RECIST v1.1., Progression Free Survival, defined as the time from randomization to first assessment of disease progression or death, whichever is earlier., Up to approximately 2 Years
Objective Response Rate, Objective Response Rate, determined using RECIST v1.1 criteria, defined as best overall response (complete or partial response) across all assessment time points., up to approximately 2 Years|Duration of Response, Duration of Response, determined using RECIST v1.1 criteria., Up to approximately 2 Years|Disease Control Rate, Disease Control Rate, determined using RECIST v1.1 criteria., Up to approximately 2 Years|Time to Response, Time to Response, defined as the time from randomization to PR or CR., Up to approximately 2 Years|Overall survival and overall survival at 6 months, 9months and 12 months, Overall survival is the time interval from the date of randomization to death due to any reason or lost of follow-up., Up to approximately 1 Year
This research study is a multicentre phase Ⅰb/Ⅱ Study to evaluate the efficacy and safety of the combination of Fluzoparib (SHR-3162) and temozolomide with or without SHR-1316 in small cell lung cancer